Non-canonical actions of Nogo-A and its receptors

详细信息    查看全文

• 作者：Stefanie Seiler^a ; ^b ; Stefano Di Santo^a ; Hans Rudolf Widmer^a ; ^{hanswi@insel.ch" class="auth_mail" title="E-mail the corresponding author}
• 关键词：ALS ; amyotrophic lateral sclerosis ; APP ; amyloid precursor protein ; BDNF ; brain-derived neurotrophic factor ; CA1 and CA3 ; cornu ammonis area 1 and 3 ; CNS ; central nervous system ; CRMP2 ; collapsin response mediator protein 2 ; CSF ; cerebral spinal fluid ; DC ; dendritic cells ; EAE ; experimental autoimmune encephalomyelitis ; EGF ; epidermal growth factor ; EGFR ; epidermal growth factor receptor ; ER ; endoplasmatic reticulum ; FGF2 ; fibroblast growth factor 2 ; FGFR1 ; fibroblast growth factor receptor 1 ; G
• 刊名：Biochemical Pharmacology
• 出版年：2016
• 出版时间：15 January 2016
• 年：2016
• 卷：100
• 期：Complete
• 页码：28-39
• 全文大小：1043 K

文摘

Nogo-A is a myelin associated protein and one of the most potent neurite growth inhibitors in the central nervous system. Interference with Nogo-A signaling has thus been investigated as therapeutic target to promote functional recovery in CNS injuries. Still, the finding that Nogo-A presents a fairly ubiquitous expression in many types of neurons in different brain regions, in the eye and even in the inner ear suggests for further functions besides the neurite growth repression. Indeed, a growing number of studies identified a variety of functions including regulation of neuronal stem cells, modulation of microglial activity, inhibition of angiogenesis and interference with memory formation. Aim of the present commentary is to draw attention on these less well-known and sometimes controversial roles of Nogo-A. Furthermore, we are addressing the role of Nogo-A in neuropathological conditions such as ischemic stroke, schizophrenia and neurodegenerative diseases.